ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • Search
  • My Favorites
    • View and print all favorites
    • Clear all favorites

Abstract Number: 226

Prevalence of Cardiovascular Disease in Patients with Gout, Osteoarthritis or Both

Daisy Bang1, Jinfeng Xu2, Robert T. Keenan3, Virginia Pike1, Aaron Lehmann1, Craig T. Tenner4, Daria Crittenden1, Michael H. Pillinger1 and Svetlana Krasnokutsky1, 1Medicine/Rheumatology, NYU School of Medicine/NYU Hospital for Joint Diseases, New York, NY, 2Biostatistics, New York University School of Medicine, New York, NY, 3Rheumatology, Duke University, Durham, NC, 4Medicine, NYU School of Medicine, New York, NY

Meeting: ACR/ARHP Annual Meeting 2015

Date of first publication: September 29, 2015

Keywords: Cardiovascular disease, gout, osteoarthritis and risk

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Metabolic and Crystal Arthropathies Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Osteoarthritis
(OA) and gout are each associated with increased cardiovascular disease (CVD),
but their relative impacts on CV risk are not known. We compared rates of CVD
among patients with OA (OA-only), gout (gout-only), or both (gout+OA).

Methods:  We used ICD-9 codes to identify male
patients from within our VA health care system with OA-only, gout-only, or gout+OA, and an active medical record between August 2007
and August 2008. For each group, we collected baseline demographics and CVD
risk factors. The primary outcome was a composite index (CV4) consisting of any
diagnosis of myocardial infarction (MI), angina, coronary bypass surgery (CABG),
and/or coronary artery disease (CAD). Secondary outcomes included individual
diagnoses within the CV4, congestive heart failure (CHF) and death. Logistic
regression was used to compare the associations of OA-only, gout-only, and gout+OA with CV outcomes, adjusting for traditional CV risk
factors: age, race, hypertension (HTN), diabetes mellitus, hyperlipidemia (HLD),
chronic kidney disease (CKD), and smoking.  

Results:  1280 gout subjects met inclusion criteria (983
gout-only, 297 gout+OA), along with 1231 OA-only
subjects. Gout subjects, with or without OA, had more CVD risk factors at
baseline, including HTN, HLD and CKD vs. OA-only. In an unadjusted model,
a diagnosis of gout increased the risk for CV4, CAD, angina, CABG, CHF, and death
compared to a diagnosis of OA-only. In a fully adjusted model, gout-only
subjects continued to have increased risk for all outcomes except MI and death
compared to OA-only subjects, while gout+OA subjects
exhibited increased risk for angina and CHF (Table 1). Gout+OA
did not impart additional risk over gout-only for any outcome except CABG.

Conclusion: Our data suggest
that gout is associated with higher risk of CVD compared with OA, that at least
some of this increased risk may be independent of traditional risk factors, and
that OA does not impart additive CVD risk to patients who also have gout.

Table 1. Relative cardiovascular disease outcomes among OA-only, Gout-only and Gout+OA subjects, adjusted for age, race, HTN, HL, DM, CKD, and smoking. Data are odds ratios with 95% confidence intervals and p-values.

Gout-only

vs

OA-only

Gout+OA

vs

OA-only

Gout+OA

vs

Gout-only

CV4

(Primary outcome)

1.271

(1.025,1.574)

p=0.029

1.263

(0.937,1.692)

p=0.121

0.994

(0.739, 1.329)

p=0.967

CAD

1.261

(1.010,1.574)

p=0.040

1.084

(0.796, 1.467)

p=0.604

0.860

(0.634, 1.159)

p=0.325

Angina

4.367

(2.005,10.609)

p<0.001

3.374

(1.233, 9.383)

p=0.017

0.773

(0.337, 1.608)

p=0.513

MI

0.972

(0.487, 1.921)

p=0.936

1.010

(0.356, 2.481)

p=0.984

1.039

(0.371, 2.529)

p=0.937

CABG

3.951

(2.249, 7.176)

p<0.001

1.782

(0.746, 3.961)

p=0.170

0.451

(0.202, 0.905)

p=0.036

CHF

2.379

(1.638, 3.483)

p<0.001

2.209

(1.378, 3.505)

p<0.001

0.929

(0.605, 1.399)

p=0.729

Death

1.30

(0.826, 2.487)

p=0.203

1.870

(0.973, 3.514)

p=0.055

1.308

(0.716, 2.317)

p=0.367


Disclosure: D. Bang, None; J. Xu, None; R. T. Keenan, AstraZeneca, 5; V. Pike, None; A. Lehmann, None; C. T. Tenner, None; D. Crittenden, Amgen Inc, 1,Amgen, Inc, 3; M. H. Pillinger, Takeda Inc, 2,AstraZeneca, 5; S. Krasnokutsky, None.

To cite this abstract in AMA style:

Bang D, Xu J, Keenan RT, Pike V, Lehmann A, Tenner CT, Crittenden D, Pillinger MH, Krasnokutsky S. Prevalence of Cardiovascular Disease in Patients with Gout, Osteoarthritis or Both [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/prevalence-of-cardiovascular-disease-in-patients-with-gout-osteoarthritis-or-both/. Accessed .
  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to ACR/ARHP Annual Meeting 2015

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-of-cardiovascular-disease-in-patients-with-gout-osteoarthritis-or-both/

Advanced Search

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology